Issues related to prescription drug pricing
Duration: August 11, 2016
to
March 15, 2019
General Issues: Health Issues , Medicare/Medicaid , Pharmacy , Budget/Appropriations
Spending: about $320,000 (But it's complicated. Here's why.)
It can be tricky to figure out how much an organization spent on a particular lobbying engagement. The law only requires lobbyists to report the amount they were paid for federal lobbying each quarter rounded to the nearest $10,000—and if it's less than $3,000 in a given quarter (or less than $13,000 for organizations with in-house lobbyists), they don't have to disclose it at all. Plus, some organizations include spending that doesn’t belong in the report—for instance, money spent lobbying state governments or other legal work.
Agencies lobbied since 2016: U.S. Senate, House of Representatives, Health & Human Services - Dept of (HHS)
Lobbyists
Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.
Lobbyist
Covered positions?
Rodney Whitlock
Health Policy Advisor to Senator Chuck Grassley
Acting Health Policy Director for Senator Chuck Grassley
Disclosures Filed
Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.
1st Quarter, 2019
ML STRATEGIES, LLC terminated an engagement in which they represented The Campaign for Sustainable Rx Pricing on March 15, 2019.
Original Filing: 301021588.xml
Lobbying Issues
Issues related to prescription drug pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Type of Issue
Health Issues Medicare/Medicaid Pharmacy
4th Quarter, 2018
In Q4, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on Jan. 18, 2019.
Original Filing: 301009269.xml
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 2051 - FAST Generics Act of 2017.
Medicare Part D Biosimilars.
H.R.6 - SUPPORT for Patients and Communities Act.
S. 3120 - HEAL Act of 2018.
S. 2553: Know the Lowest Price Act of 2018.
S. 2554: Patient Right to Know Drug Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
Medicare Part D Biosimilars.
H.R.6 - SUPPORT for Patients and Communities Act.
S. 2553: Know the Lowest Price Act of 2018.
S. 2554: Patient Right to Know Drug Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 2051 - FAST Generics Act of 2017
Medicare Part D Biosimilars.
H.R.6 - SUPPORT for Patients and Communities Act.
S. 2553: Know the Lowest Price Act of 2018.
S. 2554: Patient Right to Know Drug Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
3rd Quarter, 2018
In Q3, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on Oct. 19, 2018.
Original Filing: 300990610.xml
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 2051 - FAST Generics Act of 2017.
Medicare Part D Biosimilars.
H.R.6 - SUPPORT for Patients and Communities Act.
S. 3120 - HEAL Act of 2018.
S. 2553: Know the Lowest Price Act of 2018.
S. 2554: Patient Right to Know Drug Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
Medicare Part D Biosimilars.
H.R.6 - SUPPORT for Patients and Communities Act.
S. 2553: Know the Lowest Price Act of 2018.
S. 2554: Patient Right to Know Drug Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
H.R. 2051 - FAST Generics Act of 2017
Medicare Part D Biosimilars.
H.R.6 - SUPPORT for Patients and Communities Act.
S. 2553: Know the Lowest Price Act of 2018.
S. 2554: Patient Right to Know Drug Prices Act.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2018
In Q2, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on July 20, 2018.
Original Filing: 300973189.xml
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act.
H.R. 2051 - FAST Generics Act of 2017.
Medicare Part D Biosimilars.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
Medicare Part D Biosimilars.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
1st Quarter, 2018
In Q1, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on April 20, 2018.
Original Filing: 300954674.xml
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act.
H.R. 2051 - FAST Generics Act of 2017.
Medicare Part D Biosimilars.
The Bipartisan Budget Act of 2018, Omnibus.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
Medicare Part D Biosimilars.
The Bipartisan Budget Act of 2018, Omnibus.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act.
H.R. 2051 - FAST Generics Act of 2017.
Medicare Part D Biosimilars.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
The Bipartisan Budget Act of 2018, Omnibus.
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2017
In Q4, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on Jan. 19, 2018.
Original Filing: 300929772.xml
Lobbying Issues
Prescription drug pricing.
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act.
H.R. 2051 - FAST Generics Act of 2017
Medicare Part D Biosimilars.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Prescription drug pricing.
Medicare Part D Biosimilars.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
3rd Quarter, 2017
In Q3, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on Oct. 20, 2017.
Original Filing: 300914449.xml
Lobbying Issues
Issues related to prescription drug pricing;
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017
H.R. 2051 - FAST Generics Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to prescription drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to prescription drug pricing;
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017
H.R. 2051 - FAST Generics Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
2nd Quarter, 2017
In Q2, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on July 20, 2017.
Original Filing: 300893064.xml
Lobbying Issues
Issues related to prescription drug pricing;
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017
H.R. 2051 - FAST Generics Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to prescription drug pricing.
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
Lobbying Issues
Issues related to prescription drug pricing;
S. 974 - CREATES Act.
S. 1131 and H.R. 2439 - Fair Accountability and Innovative Research Drug Pricing Act
S. 934 and H.R. 2430 - FDA Reauthorization Act of 2017
H.R. 2051 - FAST Generics Act of 2017
Agencies Lobbied
U.S. Senate U.S. House of Representatives Health & Human Services - Dept of (HHS)
1st Quarter, 2017
In Q1, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on April 19, 2017.
Original Filing: 300871203.xml
Lobbying Issues
Issues related to prescription drug pricing; S. 3056 - CREATES Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to prescription drug pricing
Agencies Lobbied
U.S. Senate U.S. House of Representatives
4th Quarter, 2016
In Q4, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on Jan. 23, 2017.
Original Filing: 300858112.xml
Lobbying Issues
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act; 21st century cures
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to transparency and competition in the prescription drug market
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
In Q3, ML STRATEGIES, LLC lobbied for The Campaign for Sustainable Rx Pricing , earning $30,000. The report was filed on Oct. 20, 2016.
Original Filing: 300838413.xml
Lobbying Issues
Issues related to transparency and competition in the prescription drug market; FDA appropriations; S. 3056 - CREATES Act, S. 3335 Fair Drug Pricing Act
Agencies Lobbied
U.S. Senate U.S. House of Representatives
Lobbying Issues
Issues related to transparency and competition in the prescription drug market
Agencies Lobbied
U.S. Senate U.S. House of Representatives
3rd Quarter, 2016
ML STRATEGIES, LLC filed a lobbying registration on Aug. 11, 2016 to represent The Campaign for Sustainable Rx Pricing, effective Aug. 11, 2016.
Original Filing: 300823587.xml
Issue(s) they said they’d lobby about: Issues related to promoting transparency, competition and value in the prescription drug market. .
Source: Clerk of the U.S. House of Representatives and Secretary of the Senate